Liu Changfeng, Sun Jinfeng, Lu Yan, Bo Yacong
The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China.
Department of Social Medicine and Health Service Management, College of Public Health, Zhengzhou University, 450001 Zhengzhou, PR China.
PLoS One. 2016 Sep 2;11(9):e0162089. doi: 10.1371/journal.pone.0162089. eCollection 2016.
Dyslipidemia was present in most of the patients with coronary heart disease. Epidemiological evidence suggests that anthocyanin has some effects on the serum lipid. However, these results are controversial. This study aimed at collecting current clinical evidence and evaluating the effects of anthocyanin supplementation on total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in dialysis patients.
The search included PubMed, Web of Science, MEDLINE, Cochrane Library, China National Knowledge Infrastructure, Wanfang Database (up to July 2015) to identify randomized controlled trials (RCTs) on the association between anthocyanin and serum lipids. RevMan (version 5.2) was used for Meta-analysis. Meta-regression analysis, sensitivity analysis and Egger's weighted regression tests were performed by using STATA software (version 12.0; StatCorp, College Station, TX, USA).
Six studies (seven arms) involving 586 subjects were included in this meta-analysis. The results showed that anthocyanin supplementation has significant effects on TC [MD = -24.06, 95% CI(-45.58 to -2.64) mg/dL, I2 = 93%], TG [MD = -26.14, 95%CI(-40.20 to -3.08) mg/dL, I2 = 66%1], LDL-C [MD = -22.10, 95% CI (-34.36 to -9.85) mg/dL, I2 = 61%], and HDL-C(MD = 5.58, 95% CI (1.02 to 10.14) mg/dL;I2 = 90%).
Anthocyanin supplementation significantly reduces serum TC, TG, and LDL-C levels in patients with dyslipidemia, and increases HDL-C. Further rigorously designed RCTs with larger sample sizes are needed to confirm the effectiveness of anthocyanin supplementation for dyslipidemia, especially hypo high density lipoprotein cholesterolemia.
大多数冠心病患者存在血脂异常。流行病学证据表明花青素对血脂有一定影响。然而,这些结果存在争议。本研究旨在收集当前临床证据,评估补充花青素对透析患者总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)的影响。
检索了PubMed、Web of Science、MEDLINE、Cochrane图书馆、中国知网、万方数据库(截至2015年7月),以确定关于花青素与血脂关联的随机对照试验(RCT)。使用RevMan(5.2版)进行Meta分析。使用STATA软件(12.0版;美国德克萨斯州大学城StatCorp公司)进行Meta回归分析、敏感性分析和Egger加权回归检验。
本Meta分析纳入了6项研究(7个组),涉及586名受试者。结果显示,补充花青素对TC[MD = -24.06,95%CI(-45.58至-2.64)mg/dL,I2 = 93%]、TG[MD = -26.14,95%CI(-40.20至-3.08)mg/dL,I2 = 66%1]、LDL-C[MD = -22.10,95%CI(-34.36至-9.85)mg/dL,I2 = 61%]和HDL-C(MD = 5.58,95%CI(1.02至10.14)mg/dL;I2 = 90%)有显著影响。
补充花青素可显著降低血脂异常患者的血清TC、TG和LDL-C水平,并升高HDL-C。需要进一步进行更严格设计、更大样本量的RCT来证实补充花青素治疗血脂异常,尤其是低高密度脂蛋白胆固醇血症的有效性。